Aspartame Consumption and Incidence of Hematopoietic and Brain Cancers

To the Editors: Lim et al. (1), using data from the 1995 to 1996 NIH-AARP Diet and Health Study, tested the hypothesis that aspartame consumption is associated with risk of hematopoietic cancers or gliomas (2). However, inappropriateness of subjects and study protocols renders any conclusions drawn from the Lim et al. study meaningless.

Basic flaws are each significant enough to invalidate the study. (a) Estimates of aspartame consumption were based on reports of beverage consumption. Chewing gum, pharmaceuticals, and foods listed by the Aspartame Information Center (3) as containing aspartame were not considered for either supposed aspartame users or non-aspartame users. (b) Estimated average aspartame consumption for aspartame-consuming subjects was equivalent to approximately one 12 oz can of diet soda per day. Thus, we know that few, if any, heavy users of aspartame were included. (c) Subjects, AARP members over 50 years old, are not representative of the at-risk population. In addition, 52,887 responders with histories of cancer or with only death reports of cancer were excluded by Lim et al. (d) Estimates of aspartame consumption were based on answers to questions about beverage consumption during a 12-month period. Aspartame consumption during subjects’ other 49+ years was not considered. (e) Given the variability among subjects (2); the limited number of subjects who claimed to have consumed the equivalent of three, 12 oz cans or more of aspartame-containing beverages a day; and use of multivariate analyses on data wherein there were few subjects in a large number of subgroups; it is to be expected that the variability within the various groups and subgroups would be more than sufficient to obscure any difference between aspartame users and non-users (i.e., we would not expect Lim et al. to find statistically significant differences in incidence of cancers according to aspartame intake levels).

In addition to the study’s inherent flaws is the authors’ claim that their findings “are in direct contradiction with [Soffritti et al.]…” who showed that aspartame is a multipotential carcinogenic compound. But, whereas Soffritti et al. (4) fed and observed subjects over a lifetime beginning at 8 weeks, Lim et al. estimated aspartame consumption in subjects 50 years and older and observed them for no more than one tenth of their lifetimes. Inappropriateness of subjects and study protocols renders any conclusion drawn from this study meaningless. To claim that their findings “are in direct contradiction with [the work of Soffritti et al.]…” is deceptive and misleading.

Adrienne Samuels
Truth in Labeling Campaign
Chicago, IL

References
Aspartame Consumption and Incidence of Hematopoietic and Brain Cancers

Adrienne Samuels


Updated version
Access the most recent version of this article at:
http://cebp.aacrjournals.org/content/16/7/1527.3

Cited articles
This article cites 3 articles, 1 of which you can access for free at:
http://cebp.aacrjournals.org/content/16/7/1527.3.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.